Company Product Description Indication Status
Phase I
Onconano Medicine Inc., of Southlake, Texas ONM-100 Tumor imaging Various tumors Data published in Nature Communications showed drug detected residual tumor-positive margins in 9 of 9 patients in whom histology confirmed tumor-positive margins, and also detected occult lesions in an additional 5 patients whose tumors were undetected by standard of care
Phase II
Highlight Therapeutics, of Madrid, Spain (formerly Bioncotech Therapeutics) BO-112 RNA-based therapy Liver metastasis Dosed first patient in a phase IIa trial testing combination with Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with select advanced-stage solid tumors with liver metastases from colorectal cancer or gastric/gastroesophageal junction cancer; study will evaluate safety, tolerability, antitumoral activity and systemic exposure of repeated intratumoral injections
Phase III
Janssen Pharmaceutical Cos., of Johnson & Johnson, of New Brunswick, N.J. Stelara (ustekinumab) IL-12 and IL-23 antagonist Systemic lupus erythematosus Janssen decided to discontinue the Lotus study due to lack of efficacy based on data from a preplanned interim analysis

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments